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 ABSTRACT 
  Aim      To investigate the relationship between active 
inﬂ  ammatory lesions on whole-body MRI (wb-MRI) and 
new development of chronic lesions on T1 MRI in patients 
with early axial spondyloarthritis (SpA) treated either with 
etanercept (ETA) or sulfasalazine (SSZ).   
  Methods      Wb-MRIs of 65 patients treated either with 
ETA (n=35) or SSZ (n=30) over 1 year were scored for 
active inﬂ  ammation, fatty lesions, erosions and ankylosis 
in the 23 vertebral units (VUs) of the spine and in the 
sacroiliac joints (SI joints). Scoring was performed by two 
blinded radiologists.   
  Results      If there was no previous inﬂ  ammation in 
the bone no new fatty lesions occurred in SI joint 
quadrants and only a few (0.6%) in spine VUs. There 
was a signiﬁ  cant relationship between disappearance 
of inﬂ  ammation and the appearance of fatty lesions: if 
baseline inﬂ  ammation resolved fatty lesions occurred 
in 10.5% of SI joint quadrants and 17.9% of VUs. If 
inﬂ  ammation did not resolve over 1 year, fatty lesions 
occurred less frequently: 2.4% (SI joint quadrants) and 
7.2% (VUs). There was a signiﬁ  cantly higher increase of 
the mean fatty lesion score between baseline and week 
48 in the ETA (4.0 vs 4.8 for the SI joints and 1.9 vs 
2.7 for the spine) compared to the SSZ (3.0 vs 3.2 for 
the SI joints and 1.1 vs 1.2 for the spine, respectively) 
group (p=0.001 and p=0.020 for the differences). 
No signiﬁ  cant changes in the erosion or ankylosis 
score were observed in any of the two groups during 
this time.   
  Conclusions      These data indicate that there is a close 
interaction between inﬂ  ammation, tumour necrosis 
factor blockade and the development of fatty lesions in 
subchondral bone marrow of patients with axial SpA.           
  INTRODUCTION 
  Treatment of patients with active ankylosing spon-
dylitis (AS) with tumour necrosis factor α (TNFα)-
blocking agents has been proven to be highly 
effective for signs and symptoms  1    –    3   and also for 
the suppression of active inﬂ  ammation of sacroiliac 
joints (SI joints) and/or spine on MRI.  4     5   Against this 
background, the failure to retard the growth of syn-
desmophytes as shown on x-rays over a treatment 
period of 2 years was at ﬁ  rst glance a surprise,  6    –    8   
and has stimulated an intense discussion about the 
interaction between inﬂ  ammation and new bone 
formation in general and especially in the context 
of AS.  9    –    11   Indeed, it has been shown that TNFα 
blocks the activity of osteoblasts and inhibition 
of TNFα stimulates osteoblast activity in a TNF 
transgenic mouse model of arthritis.  10     12   Thus, it 
has been postulated that TNF inhibits and TNF 
blockade stimulates new bone formation.  9     11     13   In 
several investigations the question was addressed 
as to whether inﬂ   ammation is essential for the 
development of syndesmophytes or whether new 
bone formation occurs independently from previ-
ous inﬂ  ammation.  11     14     15   Although a correlation 
between inﬂ  ammation of vertebral corners at base-
line with the growth of syndesmophytes at the 
same site 2 years later was found in these analyses, 
new bone formation also occurred at sites with no 
inﬂ  ammation at baseline. 
  Inﬂ   ammation of subchondral bone marrow 
(bone marrow oedema) can be demonstrated by 
the short tau inversion recovery (STIR) sequence 
of MRI, while chronic changes are seen better or 
are only visible on MRI T1 sequence.  16     17   The MRI 
T1 sequence is unique among imaging techniques 
for the detection of fatty lesions of the bone mar-
row, which is probably the earliest sign of chronic 
changes as a consequence of inﬂ  ammation.  16     17   A 
correlation between the presence of active spon-
dylitis on MRI and the subsequent occurrence 
of fatty lesions at the same sites on MRI T1 has 
been reported recently in a preliminary study.  18   
Furthermore, a correlation between fatty lesions 
and the growth of syndesmophytes has been 
found  19   indicating that fatty inﬁ  ltration might be 
a necessary step between inﬂ  ammation and new 
bone formation. 
  In a recent study we reported a good efﬁ  cacy of 
etanercept (ETA) treatment over 1 year in patients 
with early (symptom duration less than 5 years) 
axial spondyloarthritis (SpA) on active inﬂ  amma-
tion of SI joints and the spine as shown by MRI and 
on clinical parameters, in comparison to treatment 
over the same period with sulfasalazine (SSZ).  20   In 
this prospective study patients were randomised 
to one of the two treatment arms and whole-body 
MRI (wb-MRI) was read by two scorers blinded for 
treatment and time points. 
  In the present study we analysed the develop-
ment of chronic changes in the bone on T1 MRI 
such as fatty lesions, erosions and ankylosis over 
1 year, the effect of inﬂ  ammation at baseline on 
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the development of chronic lesions and the effect of   treatment 
on the development of chronic lesions in patients from 
this trial.   
  METHODS 
  Study  design 
  Patients with axial SpA enrolled in a prospective randomised 
controlled trial were treated with ETA (n=40) versus SSZ (n=36) 
over 48 weeks.  20   All patients showed active inﬂ  ammatory 
lesions (bone marrow oedema) on wb-MRI in either the SI joints 
and/or the spine at baseline (BL).  20   
  For this analysis we included the 65 completers (35 patients 
on ETA and 30 on SSZ) in whom wb-MRI sets at baseline and 
week 48 were available. Patient characteristics are shown in 
  table 1  .       
  MRI 
  Wb-MRIs were performed at weeks 0, 24 and 48 on a 1.5 T 
scanner (Avanto TIM, Siemens, Erlangen, Germany)   according 
to a previously described protocol.  20    –    22   The STIR images were 
acquired using the following parameters: repetition time (TR) 
1660–4590, time to echo (TE) 25–83 and inversion time (TI) 150. 
The acquired T1 turbo spin-echo (TSE) images comprised a TR 
of 642–790 and a TE of 10. 
  Wb-MRIs were scored for active inﬂ  ammation  according 
to a recently described protocol  20   using the STIR sequences. 
Chronic changes were scored using the T1 sequences in the 23 
vertebral units (VUs) of the spine and the 4 quadrants of each SI 
joint in case of fatty lesions; erosions and ankylosis were only 
scored for each SI joint as shown in detail in   table 2  . Scoring 
was performed by two radiologists, blinded for treatment arm 
and MRI time point. T1 and STIR images were scored at the 
same time.   
  At baseline, the agreement between both readers (KGH, CA) 
was high for osteitis and fatty lesions with intraclass correlation 
coefﬁ  cients (ICCs) of 0.93 in the spine (SI joints 0.96) for osteitis 
and 0.97 (0.90) for fatty lesions. ICCs were lower for erosions: 
0.82 (0.80) and ankylosis 0.75 (0.96).   
  Statistics 
  Main outcome parameters were changes in chronic lesions (fatty 
lesions, erosions, ankylosis) assessed by MRI T1 sequence and 
associations between the changes in chronic lesions and changes 
in active inﬂ  ammation scores assessed by STIR sequences. To be 
able to investigate these associations the statistical analysis was 
restricted to n=65 completers (as described above). The non-
parametric analysis of covariance (non-  parametric ANCOVA) 
was used to compare the outcome of the treatment groups by 
taking the baseline status as covariable into account and the 
non-parametric Mann–Whitney test was applied to compare 
treatment groups at baseline. These analyses were based on 
means of the MRI scores of both readers (KGH, CA) on the 
patient level. Missing values at week 24 (n=3) were replaced 
by a so-called expectation maximization algorithm   (replace-
ment with an individual mean value from baseline and week 48 
adjusted for the overall trend).  23   
  To evaluate the associations between the changes in chronic 
lesions and changes in active inﬂ  ammation scores in a very 
speciﬁ  c manner these possible associations were investigated 
in the spine on the VU level and in the SI joints on the level of 
four quadrants per SI joint in case of fatty lesions and per SI 
joints for erosions and ankylosis. Regarding changes in osteitis 
scores, three groups (VUs, or quadrants) were analysed sepa-
rately; group A: both readers agree on no signs of osteitis in the 
STIR sequence in this unit at baseline and at week 48, group 
B: both readers agree regarding a resolution of inﬂ  ammation in 
this unit, group C: units not assigned to A or B but inﬂ  amma-
tion present at week 48 according to at least one reader (group 
C was not further stratiﬁ  ed because of insufﬁ  cient sample size). 
Regarding the outcome, the development of a new chronic 
lesion between baseline and week 48, an agreement between 
both readers was required. Generalised estimation equation 
(GEE) models with a logit link function were applied to inves-
tigate the associations between changes in the MRI scores for 
fatty lesions and active inﬂ  ammation. By means of these GEE 
models groups A, B and C were compared and the percentage 
of new chronic lesions and their corresponding 95% CIs were 
estimated by taking possible correlations between chronic and 
active changes in single VUs (or quadrants) within individual 
 Table  1    Baseline  characteristics   
   All   Etanercept   Sulfasalazine 
Number of patients 65 35 30
Age in years, mean (SD) 33.0 (8.5) 33.5 (8.7) 32.4 (8.4)
Male, n (%) 39 (60.0) 22 (62.9) 17 (56.7)
Symptom duration in years, 
mean (SD)
2.7 (1.7) 2.5 (1.6) 3.0 (1.8)
HLA-B27 positive, n (%) 54 (83.1) 30 (85.7) 24 (80.0)
Fulﬁ  lled modiﬁ  ed New York 
criteria,  37   n (%)
54 (50.8) 17 (48.6) 16 (53.3)
Fatty lesions on VU level, n (%) 67 (4.5) 49 (6.1) 18 (2.6)
Fatty lesions on SI joint quadrant 
level, n (%)
202 (38.8) 123 (43.9) 79 (32.9)
Erosions on VU level, n (%) 6 (0.4) 4 (0.5) 2 (0.3)
Erosions on SI joint level, n (%) 95 (73.1) 51 (72.9) 44 (73.3)
Ankylosis on VU level, n (%) 10 (0.7) 6 (0.7) 4 (0.6)
Ankylosis on SI joint level, n (%) 9 (6.9) 7 (10.0) 2 (3.3)
      Mean values of fatty lesion scores, erosion scores and ankylosis scores shown in 
 table  3 . 
  HLA, human leucocyte antigen; SI joint, sacroiliac joint; VU, vertebral unit.     
 Table  2     Scores for chronic inﬂ  ammatory changes on MRI   
  Finding on MRI    Spine score per VU 
  SI joint score per 
quadrant/joint 
Fatty lesion 0: normal bone marrow 0: fatty lesions 
absent
1: fatty lesions of <25% of VU 
area
1: fatty lesions present
2: fatty lesions of ≥25% and 
<50% of VU area
NA
3: fatty lesions of ≥50% of VU area NA
Erosions* 0: no erosion 0: normal joint margin
1: erosion <25% of vertebral end 
plate
1: 1–2 erosions
2: erosion ≥25% of vertebral end 
plate
2: 3–5 erosions
NA 3: >5 erosions
Ankylosis* 0: no ankylosis 0: ankylosis absent
1: syndesmophyte growth, not 
bridging
1: ankylosis present
2: syndesmophyte growth, 
bridging (anterior/posterior)
NA
3: transdiscal ankylosis NA
      Maximum fatty lesion score per patient: 69 for spine and 8 for SI joints; maximum 
erosion score per patient: 46 for spine and 6 for SI joints; maximum ankylosis score per 
patient 69 for spine and 2 for SI joints. 
  *Erosions and ankylosis in the spine were scored on the VU level; in the SI joints 
erosions and ankylosis were scored for left and right SI joint (not per quadrant). 
  NA, not applicable; SI joint, sacroiliac joint; VU, vertebral unit.     
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patients into account.  24   SAS software (PROC GLIMMIX; SAS, 
Cary, North Carolina, USA) was used for calculations. p Values 
<0.05 were considered statistically signiﬁ  cant.     
  RESULTS 
  Baseline  characteristics 
  The inclusion criteria and the patients’ characteristics for this trial 
have been described recently in detail.  20   Patients’ characteristics 
including chronic MRI lesions at baseline are shown in   table 1  . 
In the whole group (n=65) fatty lesions were found in 4.5% of 
VUs (in 26.2% of patients) and in 38.8% of SI joint quadrants 
(in 69.2% of patients). Erosions were found in only 0.4% of VUs 
but in 73.1% of SI joints. Ankylosis of VUs occurred in 0.7% in 
contrast to 6.9% of SI joints.   
    Occurrence of fatty lesions over 1 year in relation 
to inﬂ  ammation 
  New fatty lesions at week 48 developed in 23 VUs and in 17 SI 
joint quadrants in all patients. There was a very low rate of new 
fatty lesions of <1% (0.6% for VUs and 0% for SI joint quadrants) 
if there was no previous inﬂ  ammation in the bone (    ﬁ  gure 1A   for 
spine VUs and   ﬁ  gure 1B   for SI joint quadrants). In the presence 
of baseline inﬂ  ammation and disappearance of inﬂ  ammation at 
all subsequent time points fatty lesions occurred in 17.9% (VUs) 
and 10.5% (SI joint quadrants), while fatty lesions occurred much 
less frequently if inﬂ  ammation was present at week 48: 7.2% in 
VUs and 2.4% in SI joint quadrants (  ﬁ  gure 1A  ,  B  ). Appearance 
of new fatty lesions in the SI joints and the spine did not cor-
relate with a change in C reactive protein (SI joints: correlation 
0%
5%
10%
15%
20%
25%
(A)
(B)
(A) No active inflammation
at BL or at W48
(B) Active inflammation at
BL and no inflammation at
W48
(C) Inflammation present
at W48
% of
vertebral
units with
new fatty
lesions at
week 48
Spine, vertebral units
p=0.001 p=0.10
17.9%
(95% CI 6.1% to 42.4%)
0.6%
7.2%
(95% CI 2.7% to 18.1%)
(95% CI 0.3% to 1.5%)
0%
5%
10%
15%
(A) No active inflammation
at any time point 
(B) Active inflammation at
BL and no inflammation
at W48
(C) Inflammation present
at W48
% of SI-joint
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with new fatty
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Sacroiliac joint quadrants
p=0.004 p=0.02
0%
(95% CI 0%)
10.5%
(95% CI: 5.0% to 20.5%)
2.4%
(95% CI 1.0% to 5.6%)
 Figure  1     Frequency of newly developed fatty lesions at the vertebral units of (A) the spine and (B) the sacroiliac joint quadrants at week 48 in 
relation to active inﬂ  ammatory lesions. Percentages shown in the three groups in which (A) there was no active inﬂ  ammation at baseline (BL) 
and no inﬂ  ammation at week 48 (W48) vs (B) there was active inﬂ  ammation at baseline but no inﬂ  ammation at week 48 (disappearance of active 
inﬂ  ammation) vs (C) there was inﬂ  ammation present at week 48.       
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coefﬁ  cient=0.018, p=0.34; spine:   correlation coefﬁ  cient=0.055, 
p=0.95).       
Fatty lesions present at baseline did not disappear over 
48 weeks: 0 out of 67 (0%) at VUs and 2 out of 202 (1%) at SI 
joint quadrants. 
  When the change of active inﬂ  ammation was plotted against 
the change of the fatty lesion score also on a patient level the cor-
relation between reduction of active inﬂ  ammation and increase 
of fatty lesions can be seen (see supplementary ﬁ  gure S1). There 
was a signiﬁ  cant correlation between reduction of active inﬂ  am-
mation and increase of fatty lesions in the spine (correlation 
coefﬁ  cient=−0.39, p=0.001) as well as in the SI joints (correlation 
coefﬁ  cient=−0.76, p=0.0015).   
    Occurrence of fatty lesions compared between the two 
treatment groups 
  There was a signiﬁ  cantly higher increase of the mean fatty lesion 
score in the ETA group (4.0 at baseline vs 4.8 at week 48 for the 
SI joints and 1.9 vs 2.7 for the spine) compared to the SSZ group 
(3.0 at baseline vs 3.2 at week 48 for the SI joints and 1.1 vs 1.2 
for the spine, respectively) (p=0.001 and p=0.020 for the differ-
ences between the treatment groups) (  table 3  ). The increase in 
the fatty lesion score in the ETA group was already visible after 
24 weeks (  table 3  ).   
  The corresponding increase of the fatty lesion score on the 
patient level is shown in the probability plots in   ﬁ  gure 2A   (for 
the spine) and ﬁ  gure 2B   (for the SI joints).      When the nine patients 
who already had a maximal fatty lesion score of 8 in the SI joints 
at baseline were excluded from this analysis, the mean baseline 
values were the same (mean value 2.8) and again the increase 
in the mean fatty lesion score between baseline and week 48 
was signiﬁ  cantly (p=0.001) higher in the ETA (from 2.8 to 3.9) as 
compared to the SSZ group (from 2.8 to 3.0). 
    Figure 3   shows MRI examples without (  ﬁ  gure 3A  ) and with 
(  ﬁ  gure  3B  ) development of fatty lesions in the spine after 
  suppression of active inﬂ  ammation.     
    Development of erosions and ankylosis over 1 year 
  As shown in   table 3   there was no change in the mean erosion 
score in the whole group and also no change in the two sub-
groups (ETA vs SSZ), either in the spine or in the SI joints. The 
same was true for the mean ankylosis score. 
  Furthermore, none of the six erosions present in all VUs disap-
peared (0%). Also, there was no change in the ankylosis score in 
any of the two groups.     
  DISCUSSION 
  In this study we have clearly shown that signiﬁ  cant changes of 
fatty lesions in the SI joints and the spine can be observed over 
1 year, but not other changes on T1 MRI: (1) fatty lesions did 
not occur without previous inﬂ  ammation in the subchondral 
bone marrow, (2) the score for fatty lesions increased in patients 
treated with the TNF blocker ETA but not in patients in the con-
trol group treated with SSZ and (3) signiﬁ  cant changes in the 
fatty lesion score could already be seen after 6 months. Finally, 
(4) no changes in the erosion and ankylosis score were seen over 
1 year in any of the two treatment groups. These ﬁ  ndings might 
cast some new light on the interaction between inﬂ  ammation, 
chronic bony changes and the development of new bone forma-
tion in AS. 
  Fatty lesions seem to be the ﬁ  rst sign of chronic damage in 
the bone after previous inﬂ  ammation. This was clearly dem-
onstrated in the current study because fatty lesions occurred 
only at sites that showed subchondral bone marrow oedema 
as a sign of active osteitis at baseline, conﬁ  rming previously 
reported preliminary results.  18   Fatty lesions without previous 
inﬂ  ammation occurred very rarely. These few cases might be 
explained by the fact that MRI might have a sensitivity limit 
in the detection of inﬂ  ammation, as was shown in a previous 
study correlating MRI inﬂ  ammation and histological inﬂ  am-
mation.  25     Interestingly, fatty lesions occurred less frequently if 
inﬂ  ammation persisted, indicating that the presence of inﬂ  am-
mation might inhibit the occurrence of ‘fatty lesions’. However, 
we cannot exclude a technical problem for this part of the anal-
ysis because fatty lesions might not be detectable on an MRI T1 
sequence (hyperintense signal) if inﬂ  ammation is still present 
(hypointense signal). 
  The histological correlate of the rather imprecise MRI ﬁ  nding 
of ‘fatty lesions’ is not clear at this moment, but probably reﬂ  ects 
replacement of subchondral bone marrow by some repair tissue 
through expansion and/or activation of mesenchymal cells such 
as adipocytes, ﬁ  broblasts and osteoblasts.  26     27   
  Fatty lesions at vertebral edges on T1 MRI have also recently 
been described as early chronic bony changes, which are rela-
tively speciﬁ  c for SpA if they occur at several sites though they 
do not appear to be different from controls if present only as 
single lesions in the spine.  28     29   Thus, although fatty lesions seem 
to be useful for following up the sequence of events in SpA from 
inﬂ  ammation to chronic damage, they are not unique for SpA 
unless they show a certain pattern. 
  The signiﬁ  cant increase of fatty lesions in the group of patients 
treated with ETA over 1 year in comparison to the SSZ-treated 
group is a very interesting result of the current study. Although 
such a result seems to be a logical consequence, because ETA 
was very effective in suppressing active bone inﬂ  ammation on 
MRI in the SI joints and the spine in comparison to treatment 
with SSZ, and active suppression of inﬂ  ammation was strongly 
associated with the appearance of fatty lesions, this has not 
been shown before. Most interestingly, such a (signiﬁ  cant) dif-
ference between two treatment groups was already visible after 
6 months of treatment with a further increase of the difference 
 Table  3        Mean MRI SI joint and spine scores for fatty lesions, erosions 
and ankylosis at baseline, week 24 and week 48 in patients with axial 
spondyloarthritis treated with etanercept (ETA) or sulfasalazine (SSZ)   
 Location   MRI  parameter 
 Study  time 
point 
 ETA 
(n=35) 
 SSZ 
(n=30)   p  Value* 
Spine Fatty lesion 
score (0–69) 
(mean (SD))
Baseline† 1.9 (5.0) 1.1 (2.6)  
Week 24 2.6 (5.6) 0.9 (2.1) 0.033
Week 48 2.7 (5.8) 1.2 (2.7) 0.020
Erosion 
score (0–46) 
(mean (SD))
Baseline† 0.2 (0.4) 0.3 (0.7)  
Week 24 0.2 (0.4) 0.3 (0.8) 0.49
Week 48 0.2 (0.5) 0.3 (0.8) 0.21
Ankylosis 
score (0– 69) 
(mean (SD))
Baseline† 0.6 (2.4) 0.3 (1.1)  
Week 24 0.6 (2.3) 0.2 (1.1) 0.10
Week 48 0.7 (2.5) 0.3 (1.1) 0.52
SI joints Fatty lesion 
score (0–8) 
(mean (SD))
Baseline† 4.0 (3.2) 3.0 (2.8)  
Week 24 4.6 (3.4) 3.2 (2.9) 0.018
Week 48 4.8 (3.2) 3.2 (2.9) 0.001
Erosion 
score (0–6) 
(mean (SD))
Baseline† 3.9 (2.2) 3.5 (2.0)  
Week 24 3.8 (2.2) 3.6 (2.1) 0.060
Week 48 3.8 (2.2) 3.5 (2.2) 0.41
Ankylosis 
score (0–2) 
(mean (SD))
Baseline† 0.2 (0.6) 0.1 (0.4)  
Week 24 0.2 (0.6) 0.1 (0.4) 0.12
Week 48 0.2 (0.6) 0.1 (0.4) 0.48
      *p Values for comparison of changes in the MRI scores between both groups by 
analysis of covariance. 
  †No signiﬁ  cant differences at baseline between ETA and SSZ: (a) spine: fatty lesions 
(p=0.65), erosions (p=1.0), ankylosis (p=0.35); (b) SI joints: fatty lesions (p=0.24), 
erosions (p=0.346), ankylosis (p=0.50). 
  SI joints, sacroiliac joints.     
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after 12 months. These data suggest that fatty lesions might 
prove to be an important early outcome parameter to assess 
whether suppression of inﬂ  ammation comes early enough to 
avoid chronic changes. However, fatty lesions occurred only at 
about 10% to 20% of cleared inﬂ  ammatory sites, thus in 80% 
to 90% of inﬂ  ammatory sites inﬂ  ammation was cleared without 
the occurrence of fatty lesions. We did not ﬁ  nd an improvement 
of fatty lesions in the spine in any of the treatment groups which 
is in contrast to results from the already mentioned preliminary 
study.  19   However it is difﬁ  cult to envisage by which mechanism 
TNF blockade would reverse the presence of fatty lesions. 
  The key data presented here are further supported by the 
very similar results obtained for the SI joints and spine, both 
read blinded to time points. Furthermore, the availability of a 
control treatment group over 1 year, which was prospectively 
randomised at baseline, made it possible to compare fatty lesion 
scores between the two groups. 
  Beside fatty lesions, erosions and ankylosis are other mani-
festations of chronic damage in AS.  16     17   Erosions were observed 
in 73% of SI joints but only in 0.4% of VUs in this early axial 
SpA group. After 1 year of follow-up, we could neither ﬁ  nd a 
change in erosions nor in ankylosis in either of the two treat-
ment groups. If these patients treated with ETA are followed up 
longer than 1 year, an improvement of an erosion score might be 
detectable.  19   There was a low frequency of ankylosis at baseline, 
and no change was observed over 1 year. Though MRI is not the 
method of choice for assessing ankylosis it has been used before 
for this  17     30   and for SI joints;  16   however the role of MRI for the 
assessment of ankylosis has to be evaluated in future studies. 
  Long-term outcome in AS is determined by new bone forma-
tion (ankylosis) in the spine. Therefore the question arises as to 
how the occurrence of fatty lesions might be connected to this. 
We postulate that fatty lesions are the ﬁ  rst chronic changes after 
inﬂ  ammation and that they are necessary for the later develop-
ment of syndesmophytes. Thus, if fatty lesions can be avoided 
this might be an early (in the ﬁ  rst 6–12 months) indicator that new 
bone formation can also be avoided. Indeed, in one investigation 
radiographic syndesmophytes after 2 years were present in 12% 
 Figure  2     Cumulative probability of changes in MRI fatty lesion scores of (A) the spine and (B) the sacroiliac joints from baseline to week 48 in the 
etanercept and sulfasalazine treatment groups at the patient level. Each data point in   ﬁ  gure 2A  ,  B   represents an individual  patient.    
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of the vertebral edges that showed fatty lesions at   baseline but 
only in 2% of patients without fatty lesions at baseline,  31   sup-
porting the proposed link between inﬂ  ammation, occurrence of 
fatty lesions and new bone formation. The patients in the current 
study will be treated long term with ETA and followed up yearly 
by wb-MRI and by x-rays every 2 years, which will allow this 
question to be addressed in more detail in the future. 
  The molecular basis for the link between inﬂ  ammation and 
new bone formation in AS is still not clear. It has recently been 
shown that low serum levels of the molecules sclerostin  10   and 
Dickkopf 1 (DKK1),  32   which are both important for osteoclast 
activation and osteoblast inhibition, are associated with the 
formation of new syndesmophytes in patients with AS. Thus, 
taking all imaging and molecular data in AS together, inhibition 
and/or low levels of inﬂ  ammation are necessary for the develop-
ment of chronic lesions such as fatty lesions in subchondral bone 
marrow and the development of syndesmophytes. The results 
reported here on fatty lesions in axial SpA that might provide a 
missing link between these events. 
  With regard to TNF blocker treatment of patients with 
axial SpA, we propose the following scenario: early treatment 
might prevent the occurrence of early chronic changes such as 
fatty lesions, which was the case in about 80% of inﬂ  amma-
tory lesions that were successfully cleared by ETA treatment. 
Whether or not syndesmophytes will develop from these fatty 
lesions may no longer be dependent on TNF blocker treat-
ment but rather on the genetic background of the patients and 
on other treatments such as non-steroidal anti-inﬂ  ammatory 
drugs, which might have an effect on new bone formation.  33    –    35   
However, because continuous successful treatment with TNF 
blockers may avoid or reduce the occurrence of new inﬂ  am-
matory sites  20     36   new chronic lesions may not occur or their 
appearance may be reduced, because chronic lesions depend on 
inﬂ  ammation initially, as shown in the current study. Thus, a 
reduction of syndesmophytes growth should be detectable in 
patients treated long term with TNF blockers. However, because 
the development of the events discussed is a slow process it may 
take several years of follow-up to prove this. Future long-term 
follow-up of patients with AS treated with TNF blockers are 
necessary to conﬁ  rm the here-proposed concept. 
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